MedTrace Logo

Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19

NCT05007522 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-06-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of ketotifen and indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and indomethacin are medications approved by the Food and Drug Administration (FDA) to treat diseases other than COVID-19. Their use in this study is investigational, meaning they have not been approved by the FDA to treat COVID-19.

Conditions

  • COVID-19 Respiratory Infection

Interventions

DRUG

Ketotifen/Indomethacin

2 mg tablet, 75 mg SR tablet

DRUG

Placebo

Matching placebo tablet

Sponsors & Collaborators

Principal Investigators

  • Alexander T Limkakeng, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-03
Primary Completion
2024-06-20
Completion
2024-06-20
FDA Drug
Yes

Countries

  • Nepal

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007522 on ClinicalTrials.gov